AbbVie: Buy Or Sell Ahead Of Q1 Earnings? It's A Buy, But With Caveats (Upgrade)

Edmund InghamInvesting Group LeaderFollow5ShareSavePlay(15min)Comment(1)SummaryAbbVie Inc. is forecast to deliver robust Q1 performance, with revenues of ~$14.7bn, up ~8% year-on-year.Immunology remains ABBV's core driver, with Skyrizi and Rinvoq offsetting Humira's LOE, but patent cliffs loom in the 2030s.Oncology bets are significant but carry execution risk; pipeline diversification is limited beyond ADCs and select late-stage assets.I recommend holding or buying ABBV for its 3.3% yield and high single-digit revenue CAGR, but monitoring long-term immunology strategy is critical.In this analysis, I speculate on future product revenues to 2030 and provide some DCF analysis to suggest a target price of ~$233 - while I am bullish today, I suspect by Q127 we may have reached "peak AbbVie."Looking for a portfolio of ideas like this one? Members of Haggerston BioHealth get exclusive access to our subscriber-only portfolios. Learn More » J Studios/DigitalVision via Getty Images Investment Overview AbbVie Inc. (ABBV), the North Chicago, Illinois-based Pharma giant, is expected to report its Q1 2026 earnings around April 29th - in just under three weeks' time. A few days ago, AbbVie releasedThis article was written byEdmund Ingham14.85K FollowersFollowEdmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, discounted cash flow analysis and market by market analysis. Learn more.Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABBV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.